ABLE Member, Bharat Biotech International received approval from the Central Drugs Standard Control Organisation (CDSCO) for iNCOVACC use under Restricted Emergency Situation for ages 18 and above, in India, for heterologous booster doses.

Bharat Biotech takes a significant step forward in its fight against Covid-19. The intranasal Covid-19 vaccine iNCOVACC has been given the nod by the National drug regulator to be used as a heterologous booster. The vaccine has got approval for restricted use in emergency situations on those aged 18 years and above, after two doses of either Covishield or Covaxin. It becomes just the second approved covid-19 vaccine in India after Biological E’s Corbevax.

Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech, said, “This is a great achievement for us and the global scientific community to enable nasal administration of COVID vaccines. Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases. We thank the Ministry of Health, CDSCO, Dept of Biotechnology, Govt of India, Technology Development Board, and Washington University, St. Louis, for their support and guidance.”

ABLE Member, Bharat Biotech International received approval from the Central Drugs Standard Control Organisation (CDSCO) for iNCOVACC use under Restricted Emergency Situation for ages 18 and above, in India, for heterologous booster doses.